Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$10,949,008
-$3,757,160 QoQ
Shares Held
215,744
-77.4% QoQ
Ownership
0.294%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#60
of 210 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Blackstone Inc. holds $252,665,757 across 52 Biotechnology names. ELVN ranks #9 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AUTL |
Autolus Therapeutics plc
|
20,485,611 | $32,776,977 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
561,612 | $26,418,228 | |
| 3 | DMRA |
Damora Therapeutics, Inc.
|
1,002,971 | $26,087,275 | |
| 4 | ARTV |
Artiva Biotherapeutics, Inc.
|
2,403,437 | $23,313,338 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
237,108 | $22,565,568 | |
| 6 | ALXO |
Alx Oncology Holdings Inc
|
6,593,543 | $13,648,634 | |
| 7 | XFOR |
X4 Pharmaceuticals, Inc
|
2,681,922 | $12,524,575 | |
| 8 | IKT |
Inhibikase Therapeutics, Inc.
|
5,938,276 | $12,054,700 |
All Filings in ELVN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,949,008 | 215,744 | Shares | Other | 2026-08-14 | |
| 2025-12-31 | $14,706,168 | 954,946 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $27,032,518 | 1,320,592 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $26,491,075 | 1,320,592 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $15,002,201 | 762,307 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $8,399,767 | 373,323 | Shares | Other | 2025-02-14 | |
| 2024-09-30 | $9,534,669 | 373,323 | Shares | Other | 2024-11-14 | |
| 2024-06-30 | $7,505,976 | 321,180 | Shares | Other | 2024-08-14 | |
| 2024-03-31 | $443,109 | 25,191 | Shares | Other | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||